|Bid||47.00 x 100|
|Ask||48.51 x 5200|
|Day's Range||47.33 - 47.88|
|52 Week Range||36.81 - 50.24|
|PE Ratio (TTM)||11.54|
|Dividend & Yield||1.64 (3.41%)|
|1y Target Est||53.25|
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
GUILDFORD, England , July 21, 2017 /PRNewswire/ -- FOR UK MEDIA ONLY First investigational targeted biologic in the European Union to receive positive CHMP opinion for atopic dermatitis Sanofi and its ...
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent ® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis - First investigational targeted biologic in the European ...